2 ms·
At about the same time, Pfizer and BioNTech spoke with Graham about using the 2P mutation in their vaccine. Because their work was patented and widely published
by maxerickson 6y ago
At about the same time, Pfizer and BioNTech spoke with Graham about using the 2P mutation in their vaccine. Because their work was patented and widely published, other drugmakers—including Novavax and Johnson & Johnson—also based their candidates on the design. Pfizer-BioNTech’s vaccine would become the first authorized in the U.S. after it showed an impressive 95-percent efficacy rate. Moderna’s vaccine was 94-percent effective.
(at least) 4 of the vaccine candidates utilize the research from the article.